Skip to main content
. 2011 Dec 9;11:512. doi: 10.1186/1471-2407-11-512

Table 1.

Comparison between K562 Gleevec-treated group versus K562 control group.

A. K562 Gleevec-treated group versus K562 control group
Function Enrichment Score Enrichment p-value # genes in list, in group

KEGG JAK STAT SIGNALING PATHWAY 12.616000 0.000003 8

ST STAT3 PATHWAY 6.219490 0.001990 2

B. JAK-STAT Signaling Pathway

Gene Symbol Definition p-value(K562 Treated vs. K562 Control) Fold-Change
(K562 Treated vs. K562 Control)

BCL2L1 Homo sapiens BCL2-like 1 (BCL2L1), nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA. 0.000076 -2.336810

CISH Homo sapiens cytokine inducible SH2-containing protein (CISH), mRNA. 0.000754 -2.926860

CCND1 Homo sapiens cyclin D1 (CCND1), mRNA. 0.000964 -9.480380

SPRED1 Homo sapiens sprouty-related, EVH1 domain containing 1 (SPRED1), mRNA. 0.001425 -3.138930

SOCS1 Homo sapiens suppressor of cytokine signaling 1 (SOCS1), mRNA. 0.003518 -2.455500

IL6 Homo sapiens interleukin 6 (interferon, beta 2) (IL6), mRNA. 0.004541 -2.036640

PIK3CG Homo sapiens phosphoinositide-3-kinase, catalytic, gamma polypeptide (PIK3CG), mRNA. 0.005740 -2.292180

PIM1 Homo sapiens pim-1 oncogene (PIM1), mRNA. 0.006760 -2.343000

(a) Gene set analysis showing enrichment of gene sets under JAK/STAT pathway. These gene sets showed the number of genes that are downregulated in this pathway in K562 Gleevec-treated cells. (b) List of downregulated genes related to JAK/STAT pathway in K562 Gleevec-treated cells